Viability and Function of Platelet Concentrates Stored in CPD‐Adenine (CPDA‐1)

Publisher Website
Google Scholar
Abstract
The effective use of CPDA-1 [citrate-phosphate-dextrose-adenine] as an anticoagulant in routine [human] blood banking practice requires demonstration that platelet concentrates prepared in this solution meet both in vitro quality control standards and maintain posttransfusion viability and function after storage. In 138 units of CPDA-1 platelet concentrates, the average platelet count was 8.0 .+-. 0.2 .times. 1010 with 81% of the units having > 5.5 .times. 1010 platelets. The mean poststorage pH was 6.68 .+-. 0.03 and only 4 of the units had a pH of < 6.0 (3%). Residual plasma volume averaged 75 .+-. 1 ml. Platelet viability was determined in 16 normal volunteers by measuring survival of 51Cr-labeled autologous platelets after storage for 72 h at 22 .+-. 2.degree. C. Platelet recovery averaged 50 .+-. 4%, while survival was 7.3 .+-. 0.4 days for the 15 units with a pH > 6.0. Measurements of posttransfusion platelet viability and function were made in 12 patients with thrombocytopenia secondary to marrow failure. Their mean pretransfusion platelet count was 17,000 .+-. 2000/.mu.l, and their standardized template bleeding times were all > 30 min. Platelet recovery averaged 44 .+-. 5% and survival 3.3 .+-. 0.5 days. In 7 of the patients with the best posttransfusion increments, bleeding time was improved. Five patients with poor posttransfusion platelet increments showed no improvement in bleeding time with CPDA-1; 2 of these patients were also transfused with CPD platelets and had no response. Platelet concentrates prepared in CPDA-1 meet in vitro quality control standards. After transfusion, they maintain viability and function comparable to that of CPD collected platelets.